600699.SS
Ningbo Joyson Electronic Corp.
ShanghaiCNYEQUITY
Consumer Cyclical
DELAYED
Last price
18.97
▼ 0.45 (2.32%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
19.35
Prev close
19.42
Day high
19.78
Day low
18.88
Volume
14.94M
Market cap
$29.42B
P/E (TTM)
19.56
52W range
18.88 – 39.98
Day trading desk
Gap from prior close
-0.36%
Prior close 19.42
VWAP
19.14
-0.88% from price
Relative volume
0.69×
Normal
Session range
4.56%
18.88 – 19.74
Position in range
10%
Near session low
ATR (14D)
0.62
3.28% of price
Prior day high
19.42
PDH
Prior day low
19.01
PDL
Bid / ask spread
—
Quote not published
Session volume
25.31M
Avg 36.76M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-9.58%
-8.2%
1M
-1.15%
-4.9%
3M
-40.63%
-43.7%
6M
-32.08%
-43.1%
YTD
-39.51%
-51.8%
1Y
+1.66%
-18.3%
3Y
-7.37%
-81.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on 600699.SS open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
621.47M
Total on file
Fundamentals
Market cap$29.42B
Enterprise value$51.94B
Revenue (TTM)$60.42B
Gross profit$10.53B
EBITDA$5.38B
Net income$1.40B
EPS (TTM)$0.97
Free cash flow$1.18B
Total cash$12.05B
Total debt$26.80B
Book value / share$11.40
Shares outstanding1.40B
Float971.11M
Short % of float—
Dividend yield0.93%
Beta (5Y)0.76
Valuation & profitability ratios
Trailing P/E19.56
Forward P/E12.72
PEG ratio—
Price / sales—
Price / book1.66
EV / revenue0.86
EV / EBITDA9.66
Gross margin17.43%
Operating margin5.59%
Profit margin2.31%
Return on equity7.43%
Return on assets3.22%
Debt / equity107.83
Current ratio1.32
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $61.18B | $55.86B | $55.73B | $49.79B | +9.5% |
| Operating revenue | $61.18B | $55.86B | $55.73B | $49.79B | +9.5% |
| Cost of revenue | $49.99B | $46.80B | $47.67B | $43.84B | +6.8% |
| Gross profit | $11.20B | $9.06B | $8.06B | $5.95B | +23.5% |
| Research & development | $3.29B | $2.58B | $2.54B | $2.14B | +27.2% |
| Selling, general & admin | $1.47B | $1.54B | $1.33B | $1.32B | -4.6% |
| Total operating expense | $7.54B | $6.25B | $5.63B | $5.39B | +20.6% |
| Operating income | $3.65B | $2.81B | $2.43B | $568.53M | +30.0% |
| Net interest income | -$1.06B | -$1.04B | -$1.07B | -$859.43M | -1.8% |
| Pre-tax income | $2.19B | $2.00B | $1.76B | $479.82M | +9.5% |
| Tax provision | $569.68M | $669.47M | $522.19M | $246.56M | -14.9% |
| Net income | $1.34B | $960.47M | $1.08B | $394.18M | +39.1% |
| Net income to common | $1.34B | $960.47M | $1.08B | $394.18M | +39.1% |
| Basic EPS | 0.95 | 0.69 | 0.78 | 0.29 | +37.7% |
| Diluted EPS | 0.95 | 0.69 | 0.78 | 0.29 | +37.7% |
| EBIT | $3.33B | $3.13B | $2.88B | $1.41B | +6.5% |
| EBITDA | $6.73B | $6.29B | $5.77B | $4.28B | +6.9% |
| Basic shares | 1.41B | 1.39B | 1.39B | 1.36B | +1.0% |
| Diluted shares | 1.41B | 1.39B | 1.39B | 1.36B | +1.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $9.00B | $7.26B | $5.18B | $5.40B | +24.0% |
| Cash & short-term investments | $9.34B | $7.41B | $5.46B | $5.87B | +26.1% |
| Accounts receivable | $8.82B | $8.68B | $8.03B | $7.60B | +1.7% |
| Inventory | $10.68B | $10.54B | $9.25B | $8.51B | +1.4% |
| Total current assets | $32.60B | $30.09B | $26.36B | $24.98B | +8.4% |
| Property, plant & equipment | $17.53B | $16.93B | $14.52B | $14.10B | +3.6% |
| Goodwill & intangibles | $13.55B | $13.29B | $10.14B | $9.75B | +2.0% |
| Total assets | $69.15B | $64.17B | $56.89B | $54.11B | +7.8% |
| Total current liabilities | $33.34B | $25.74B | $22.63B | $20.88B | +29.5% |
| Current debt | $5.46B | $4.96B | $4.24B | $3.01B | +10.0% |
| Long-term debt | $8.39B | $15.19B | $11.96B | $12.47B | -44.8% |
| Total debt | $24.70B | $24.76B | $20.39B | $20.26B | -0.2% |
| Total liabilities | $45.13B | $44.32B | $37.76B | $36.41B | +1.8% |
| Retained earnings | $3.33B | $2.37B | $1.81B | $901.31M | +40.7% |
| Shareholder equity | $17.32B | $13.56B | $13.58B | $12.25B | +27.8% |
| Working capital | -$739.13M | $4.35B | $3.73B | $4.10B | -117.0% |
| Net tangible assets | $3.77B | $271.05M | $3.44B | $2.50B | +1,290.6% |
| Shares issued | 1.55B | 1.41B | 1.41B | 1.37B | +10.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $1.62B | $1.33B | $1.24B | $233.26M | +21.8% |
| Depreciation & amortisation | $3.40B | $3.17B | $2.89B | $2.87B | +7.3% |
| Change in working capital | -$1.17B | -$1.03B | -$1.12B | -$1.69B | -13.8% |
| Operating cash flow | $5.40B | $4.60B | $3.93B | $2.17B | +17.3% |
| Capital expenditure | -$4.31B | -$3.21B | -$3.77B | -$3.30B | -34.1% |
| Investing cash flow | -$4.15B | -$1.99B | -$2.83B | -$2.67B | -108.5% |
| Dividends paid | -$1.54B | -$1.51B | -$1.04B | -$762.93M | -2.3% |
| Financing cash flow | $643.75M | -$871.54M | -$726.05M | -$230.94M | +173.9% |
| Free cash flow | $1.09B | $1.39B | $158.59M | -$1.13B | -21.5% |
| End cash position | $7.96B | $5.98B | $4.25B | $3.85B | +33.2% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $13.82B | $15.34B | — | $15.77B | $14.58B | $14.73B | -9.9% |
| Operating revenue | $13.82B | $15.34B | — | $15.77B | $14.58B | $14.73B | -9.9% |
| Cost of revenue | $11.37B | $12.54B | — | $12.87B | $11.97B | $12.08B | -9.3% |
| Gross profit | $2.44B | $2.80B | — | $2.90B | $2.61B | $2.65B | -12.9% |
| Research & development | $839.40M | $731.18M | — | $897.09M | $796.43M | $813.32M | +14.8% |
| Selling, general & admin | $825.14M | -$1.54B | — | -$315.42M | $912.29M | -$672.51M | +153.6% |
| Total operating expense | $1.68B | $1.94B | — | $1.92B | $1.72B | $2.25B | -13.5% |
| Operating income | $764.11M | $862.84M | — | $981.37M | $892.10M | $406.20M | -11.4% |
| Net interest income | -$248.93M | -$230.18M | -$285.65M | -$253.36M | -$294.54M | — | -8.1% |
| Pre-tax income | $582.41M | $340.90M | — | $656.88M | $590.06M | $223.77M | +70.8% |
| Tax provision | $119.69M | $88.10M | — | $151.18M | $186.96M | $160.39M | +35.9% |
| Net income | $402.09M | $215.58M | — | $367.18M | $340.45M | $18.97M | +86.5% |
| Net income to common | $402.09M | $215.58M | — | $367.18M | $340.45M | $18.97M | +86.5% |
| Basic EPS | 0.26 | — | — | — | 0.24 | — | — |
| Diluted EPS | 0.26 | — | — | — | 0.24 | — | — |
| EBIT | $868.21M | $591.65M | $914.18M | $933.33M | $890.58M | — | +46.7% |
| EBITDA | $868.21M | $591.65M | $914.18M | $933.33M | $890.58M | — | +46.7% |
| Basic shares | 1.55B | — | — | — | 1.42B | — | — |
| Diluted shares | 1.55B | — | — | — | 1.42B | — | — |
| Line item | 2026-03-31 | 2025-12-31 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $11.61B | $9.00B | $7.27B | $7.86B | $7.26B | +28.9% |
| Cash & short-term investments | $12.05B | $9.34B | $7.75B | $8.58B | $7.41B | +29.0% |
| Accounts receivable | $8.16B | $8.82B | $9.09B | $8.90B | $8.68B | -7.5% |
| Inventory | $10.44B | $10.68B | $11.07B | $11.23B | $10.54B | -2.3% |
| Total current assets | $34.54B | $32.60B | $31.66B | $32.21B | $30.09B | +5.9% |
| Property, plant & equipment | $16.93B | $17.53B | $17.73B | $17.23B | $16.93B | -3.4% |
| Goodwill & intangibles | $13.57B | $13.55B | $13.89B | $13.47B | $13.29B | +0.1% |
| Total assets | $70.84B | $69.15B | $68.16B | $67.04B | $64.17B | +2.4% |
| Total current liabilities | $26.25B | $33.34B | $29.31B | $27.10B | $25.74B | -21.3% |
| Current debt | $5.38B | $5.46B | $6.11B | $5.83B | $4.96B | -1.6% |
| Long-term debt | $16.51B | $8.39B | $14.31B | $16.14B | $15.19B | +96.8% |
| Total debt | $26.79B | $24.70B | $27.12B | $27.04B | $24.76B | +8.5% |
| Total liabilities | $45.99B | $45.13B | $47.34B | $46.81B | $44.32B | +1.9% |
| Retained earnings | $3.73B | $3.33B | $2.71B | $2.71B | $2.37B | +12.1% |
| Shareholder equity | $17.53B | $17.32B | $13.97B | $13.68B | $13.56B | +1.2% |
| Working capital | $8.28B | -$739.13M | $2.35B | $5.12B | $4.35B | +1,220.7% |
| Net tangible assets | $3.95B | $3.77B | $79.35M | $210.92M | $271.05M | +4.9% |
| Shares issued | 1.55B | 1.55B | 1.41B | 1.41B | 1.41B | 0.0% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|
| Capital expenditure | -$1.06B | -$1.24B | -$1.12B | -$825.31M | -$724.77M | +14.2% |
| Investing cash flow | -$1.67B | -$806.01M | -$716.11M | -$1.75B | -$509.92M | -107.8% |
| Dividends paid | -$250.58M | -$220.99M | -$751.09M | -$282.18M | -$245.99M | -13.4% |
| Financing cash flow | $3.30B | $1.02B | -$878.39M | $1.04B | -$1.55B | +222.5% |
| Free cash flow | -$148.84M | $517.86M | -$81.84M | $42.24M | $826.60M | -128.7% |
| End cash position | $8.38B | $7.96B | $5.72B | $6.19B | $5.98B | +5.3% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Mar 2026 | 0.32 | 0.23 | -27.0% |
| Dec 2025 | — | 0.26 | — |
| Sep 2025 | 0.21 | 0.30 | +42.9% |
| Jun 2025 | 0.23 | 0.27 | +17.4% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.26 | 2 | $0 | — |
| Next quarter | 0.28 | 2 | $0 | — |
| Current year | 1.22 | 4 | $64.86B | +6.0% |
| Next year | 1.49 | 5 | $68.63B | +8.3% |
Analyst targets & ownership
Mean target$31.98
High target$43.00
Low target$20.00
Implied upside68.61%
Analyst count16
ConsensusNONE
Strong buy / Buy0 / 13
Hold5
Sell / Strong sell0 / 0
Held by insiders40.41%
Held by institutions7.26%
Institutions holding142
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
20.35
-6.80% from price
SMA 20
20.59
-7.88% from price
SMA 50
21.30
-10.92% from price
SMA 100
24.46
-22.46% from price
SMA 200
26.22
-27.65% from price
EMA 12
20.15
-5.84% from price
EMA 26
20.65
-8.15% from price
EMA 50
21.69
-12.53% from price
RSI (14)
32.7
Neutral
MACD (12,26,9)
-0.51
Hist -0.14
ATR (14)
0.62
3.28% of price
Realised vol 30D
40.0%
Annualised
Bollinger upper
22.15
20, 2σ
Bollinger lower
19.04
20, 2σ
50 / 200 cross
Death
21.30 vs 26.22
Trend bias
Below 200
-27.65%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.51
Less volatile than market
Correlation to SPY
0.13
Largely independent
Realised vol 30D
40.0%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-49.1%
Peak to trough
Max drawdown 5Y
-59.6%
Peak to trough
ATR 14
0.62
3.28% of price
Beta (reported)
0.76
5Y monthly, from filing
Dividends & splits
Forward rate$0.18 / yr
Forward yield0.93%
5-year avg yield—
Payout ratio26.80%
Ex-dividend dateJun 2, 2026
Next pay date—
Last split1.4:1
Split dateJul 29, 2019
Headlines
3 Unpopular Stocks We Steer Clear Of
StockStory · 9m ago
Oleria and Happiest Minds Partner to Accelerate Modern Identity Governance for AI-First Enterprises
ACCESS Newswire · 12m ago
Vicore Pharma to Present at the European Respiratory Society Congress 2026
ACCESS Newswire · 12m ago
Dollar trading near multi-month lows, restrained by debt nerves
Reuters · 12m ago
Billionaire Investor Stanley Druckenmiller Sold Broadcom, Intel, and Micron and Bought Another Chip Stock That Expects to Double Data Center Sales in 2027
Motley Fool · 22m ago
TME Pharma provides update on its activities
GlobeNewswire · 22m ago
American Chemical Society Names Syngenta's Camilla Corsi the 2026 Winner of Prestigious International Award for Research in Agrochemicals
Business Wire · 27m ago
Valerio Therapeutics Announces Signing of Definitive Agreements for the Acquisition of Etherna Immunotherapies, Building a Leading Platform in Targeted RNA, and €40.25 Million PIPE Financing From New and Existing Investors
Business Wire · 27m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.